

PCTWORLD INTELLECTUAL
Interna

INTERNATIONAL APPLICATION PUBLISHED U

(51) International Patent Classification ⁶ :C07D 409/12, A61K 31/33, C07D 405/12,
401/12

A1

WO 9602537A1

(43) International Publication Date: 1 February 1996 (01.02.96)

(21) International Application Number: PCT/EP95/02637

(22) International Filing Date: 6 July 1995 (06.07.95)

(30) Priority Data:
9414139.7 13 July 1994 (13.07.94) GB(71) Applicant (for all designated States except US): SMITHKLINE
BEECHAM PLC [GB/GB]; New Horizons Court, Brentford,
Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FORBES, Ian, Thomson
[GB/GB]; SmithKline Beecham Pharmaceuticals, Coldhar-
bour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).
JONES, Graham, Elgin [GB/GB]; SmithKline Beecham
Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow,
Essex CM19 5AD (GB). KING, Francis, David [GB/GB];
SmithKline Beecham Pharmaceuticals, Coldharbour Road,
The Pinnacles, Harlow, Essex CM19 5AD (GB). HAM, Pe-
ter [GB/GB]; SmithKline Beecham Pharmaceuticals, Cold-
harbour Road, The Pinnacles, Harlow, Essex CM19 5AD
(GB). DAVIES, David, Thomas [GB/GB]; SmithKline
Beecham Pharmaceuticals, Coldharbour Road, The Pinna-
cles, Harlow, Essex CM19 5AD (GB). MOGHE, Angela[GB/GB]; SmithKline Beecham Pharmaceuticals, Coldhar-
bour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).(74) Agent: SUMMERSELL, Richard, John; SmithKline Beecham,
Corporate Intellectual Property, SB House, Great West
Road, Brentford, Middlesex TW8 9BD (GB).(81) Designated States: JP, US, European patent (AT, BE, CH, DE,
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).**Published***With international search report.*(54) Title: BENZOCONDENSED FIVE MEMBERED HETEROCYCLE CARBOXAMIDES AS 5HT_{2B/2C} RECEPTOR ANTAGO-
NISTS

(57) Abstract

Novel heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and
to their use in the treatment of CNS disorders are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

BENZOCONDENSED FIVE MEMBERED HETEROCYCLE CARBOXAMIDES AS 5HT_{2B/2C} RECEPTOR ANTAGONISTS

This invention relates to compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

WO 94/04533 (SmithKline Beecham plc) describes indole and indoline derivatives which are described as possessing 5HT_{2C} receptor antagonist activity. A structurally distinct class of compounds has now been discovered, which have been found to have 5HT_{2C} receptor antagonist activity. Some or all of the compounds of the invention also exhibit 5HT_{2B} antagonist activity. 5HT_{2C/2B} receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS.

The present invention therefore provides, in a first aspect, a compound of formula (I) or a salt thereof:



wherein:

P represents phenyl, a quinoline or isoquinoline residue, or a 5-membered or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;

X and Y are independently selected from oxygen, sulphur, carbon, nitrogen, C=O, CH, CH₂ or NR⁴ where R⁴ is hydrogen or C₁₋₆ alkyl;

Z is carbon, nitrogen or CH and the dotted lines represent optional double bonds;

R¹ is hydrogen, C₁₋₆ alkyl, halogen, CF₃, NR⁷R⁸ or OR⁹ where R⁷, R⁸ and R⁹ are independently hydrogen, C₁₋₆ alkyl or arylC₁₋₆alkyl;

R² is hydrogen or C₁₋₆ alkyl;

n is 0 to 3; and

R³ groups are independently C₁₋₆ alkyl optionally substituted by one or more halogen atoms, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-

C₁₋₆ alkyl, C₁₋₆ alkylthio, C₃₋₆cycloalkylthio, C₃₋₆ cycloalkylC₁₋₆ alkylthio, halogen, nitro, CF₃, OCF₃, SCF₃, SO₂CF₃, SO₂F, formyl, C₂₋₆ alkanoyl, cyano, optionally substituted phenyl or thienyl, NR⁷R⁸, CONR⁷R⁸, or OR⁹ where R⁷, R⁸ and R⁹ are as defined for R¹, CO₂R¹⁰ where R¹⁰ is hydrogen or C₁₋₆ alkyl; or two adjacent R³ groups together form an optionally substituted 5-membered heterocyclic ring;

provided that when X and Y are both CH₂, Z is other than nitrogen.

C₁₋₆ Alkyl groups, whether alone or as part of another group, may be straight chain or branched.

10 The amide moiety can be attached to a carbon or any available nitrogen atom of the ring P, preferably it is attached to a carbon atom. Suitable moieties when the ring P is a 5-membered aromatic heterocyclic ring include isothiazolyl, isoxazolyl, thiadiazolyl and triazolyl. Suitable moieties when the ring P is a 6-membered aromatic heterocyclic ring include, for example, pyridyl, pyrimidyl or pyrazinyl.

15 When P is quinoline, or an isoquinoline residue, the amide moiety can be attached at any position of the ring, preferably to the 4- or 5-position. Preferably P is pyridyl, in particular 3-pyridyl.

Suitably X and Y are independently selected from oxygen, sulphur, carbon, nitrogen, C=O, CH, CH₂ or NR⁴ where R⁴ is hydrogen or C₁₋₆ alkyl and Z is selected from carbon, CH or nitrogen such that X, Y and Z together with the phenyl group to which they are attached form a 5,6 bicyclic ring system. Examples of such ring systems include benzothiophene, benzofuran, indene and indole. Preferably X is oxygen, sulphur or NR⁴, Z is carbon and Y is CH, i.e. Z-Y is a C=CH group such that X, Y and Z together with the phenyl group to which they are attached form part of a benzofuran, benzothiophene or indole ring.

Preferably R¹ is hydrogen.

Preferably R² is hydrogen.

Suitably R³ groups are independently C₁₋₆ alkyl optionally substituted by one or more halogen atoms, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₆ alkyl, C₁₋₆ alkylthio, C₃₋₆cycloalkylthio, C₃₋₆ cycloalkylC₁₋₆ alkylthio, halogen, nitro, CF₃, OCF₃, SCF₃, SO₂CF₃, SO₂F, formyl, C₂₋₆ alkanoyl, cyano, optionally substituted phenyl or thienyl, NR⁷R⁸, CONR⁷R⁸, or OR⁹ where R⁷, R⁸ and R⁹ are as defined for R¹, CO₂R¹⁰ where R¹⁰ is hydrogen or C₁₋₆ alkyl. When R³ is phenyl or thienyl, optional substituents include those listed above for R¹.

35 When two adjacent R³ groups together form an optionally substituted 5-membered heterocyclic ring examples of such rings include thienyl, furyl and pyrrollyl rings. When n is greater than 1 the resulting R³ groups can be the same or different.

Preferably n is 2. Preferably an indoline, benzofuran or benzothiophene ring is disubstituted in the 5- and 6-positions. Preferably the 5-position is substituted by halogen or trifluoromethyl and the 6-position is substituted by C₁₋₆alkyl such as methyl or C₁₋₆alkoxy such as methoxy, or C₁₋₆alkylthio such as methylthio.

5 Particular compounds of the invention include:

- 5-Bromo-6-methoxy-N-(3-pyridyl)benzo-[b]thiophene-3-carboxamide,
 6-Methoxy-N-(3-pyridyl)-5-trifluoromethylbenzo[b]thiophene-3-carboxamide,
 5-Bromo-6-methoxy-N-(3-pyridyl)benzo[b]furan-3-carboxamide,
 6-Methoxy-N-(3-pyridyl)-5-trifluoromethylbenzo[b]furan-3-carboxamide,
 10 5-Bromo-6-methoxy-N-(3-pyridyl)indole-3-carboxamide,
 6-Methoxy-1-methyl-N-(3-pyridyl)-5-trifluoromethylindole-3-carboxamide,
 5-Chloro-6-methyl-N-(3-pyridyl)benzothiophene-3-carboxamide,
 5-Thiomethyl-6-trifluoromethyl-1-(3-pyridylcarbonyl)-indole,
 and pharmaceutically acceptable salts thereof.


15 The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic acids.

20 Certain compounds of formula (I) may also form N-oxides or solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or
 25 any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.


The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process
 30 comprises:

the coupling of a compound of formula (II);



35

with a compound of formula (III):



5 wherein n, X, Y, Z and P are as defined in formula (I), A and B contain the appropriate functional group(s) necessary to form the moiety $-NR^{2'}CO$ when coupled, the variables $R^{1'}$, $R^{2'}$ and $R^{3'}$ are R^1 , R^2 , and R^3 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any $R^{1'}$, $R^{2'}$ and $R^{3'}$, when other than R^1 , R^2 and R^3 respectively to R^1 , R^2 and R^3 , interconverting R^1 , R^2 and R^3 and forming a pharmaceutically acceptable salt thereof.

10 Preferably A is $-NHR^{2'}$ and B is COL wherein $R^{2'}$ is as defined above and L is a leaving group. Such compounds can be reacted using standard chemistry. Examples of suitable compounds of formula (III) include acyl halides in which the leaving group L is halogen such as chloro. Activated compounds of formula (III) can also be prepared by reaction of the corresponding carboxylic acid with a coupling reagent such as carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphoryl azide.

20 R^3 groups can be introduced at any suitable stage in the process, preferably R^3 groups are introduced at an early stage in the process. It should be appreciated that it is preferred that all groups R^1 to R^3 are introduced before coupling compounds of formula (II) and (III).

25 Suitable examples of groups $R^{1'}$, $R^{2'}$ and $R^{3'}$ which are convertible to R^1 , R^2 and R^3 alkyl groups respectively, include acyl groups which are introduced conventionally and may be converted to the corresponding alkyl group by conventional reduction, such as using sodium borohydride in an inert solvent followed by hydrogenolysis in an inert solvent. Hydrogen substituents may be obtained from alkoxy carbonyl groups which may be converted to hydrogen by hydrolysis and decarboxylation. When R^3 is hydroxy it is preferably protected in the compound of formula (II) as, for example, benzyl which is removed by hydrogenation.


30 Suitable examples of a group $R^{2'}$ which are convertible to R^2 , include alkoxy carbonyl and benzyl or *para*-methoxybenzyl which are converted to the group where R^2 is hydrogen using conventional conditions.

35 Interconversions of R^1 , R^2 and R^3 are carried out by conventional procedures. For example R^1 halo and R^3 halo may be introduced by selective

halogenation of the ring P or the benzene ring of the indoline group using conventional conditions. It should be appreciated that it may be necessary to protect any R¹ to R³ hydrogen variables which are not required to be interconverted.

Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981).

Compounds of formula (II) in which A is NHR^{2'} are known compounds or can be prepared analogously to known compounds. As mentioned above, compounds of formula (III) are prepared from the corresponding acids, that is to say, compounds of formula (IV):



in which n, X, Y, Z and R^{3'} are as defined in formula (III). Compounds of formula (IV) are either commercially available or may be prepared according to known methods or analogous to known methods. Novel intermediates of formula (III) also form part of the invention.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative. N-oxides may be formed conventionally by reaction with hydrogen peroxide or percarboxylic acids.

Compounds of formula (I) and their pharmaceutically acceptable salts have 5HT_{2B/2C} receptor antagonist activity and are believed to be of potential use for the treatment or prophylaxis of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS.

Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.

The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a

pharmaceutically acceptable salt thereof.

In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of the above disorders.

5 The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

15 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

20 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.

25 For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, 30 preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can 35 be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

5 The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg;
10 and such therapy may extend for a number of weeks or months.

When administered in accordance with the invention, no unacceptable toxicological effects are expected with the compounds of the invention.

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

Description 1**3-Methoxy-4-bromoaniline (D1)**

5 2-Bromo-5-nitroanisole (31g, 134 mmoles) in methanol (700 ml) was added to a mixture of iron powder (22.5g, 400 mmoles), and ammonium chloride (33.5g, 630 mmoles) in water (600 ml). The mixture was heated under reflux for 3 hrs. The mixture was allowed to cool and filtered. The filtrate was concentrated *in vacuo* and the residue partitioned between water and dichloromethane. The organic phase was
10 dried (Na₂SO₄), filtered and evaporated to dryness to give the title compound (D1) (25g, 93%).

NMR (CDCl₃) δ: 3.60-3.75 (2H, br s), 3.81 (3H, s), 6.12-6.19 (1H, m), 6.21 (1H, s),
15 7.23 (1H, d, J=8Hz)

15

Description 2**3-Methoxy-4-bromobenzenethiol (D2)**

3-Methoxy-4-bromoaniline (D1) (14.0g, 69 mmoles) was diazotised in concentrated
20 hydrochloric acid/ice-water 50:50 (40 ml) by treating with sodium nitrite (5.0g, 72 mmoles). The diazonium salt was then added very slowly to a solution of ethyl potassium xanthate (12.2g, 76 mmoles) in water (20 ml) at 55° C. The resulting xanthate ester was subjected to base hydrolysis followed by acid-base extraction to give the title compound (D2) (8.1g, 53%)*

25

NMR (CDCl₃) δ: 3.50 (1H, s), 3.85 (3H, s), 6.71-6.82 (2H, m), 7.38 (1H, d, J =
8Hz).

* Detailed procedure: D.S. Tarbell, D.K. Fukushima, Organic Synthesis, Collective
30 Volume III, p809.

Description 3**Ethyl 3-(3-methoxy-4-bromophenylthio)-2-oxopropanoate (D3)**

35 3-Methoxy-4-bromobenzenethiol (D2) (9.6g, 44 mmoles) in pyridine (30 ml) was treated with ethyl bromopyruvate (5.9 ml, 46 mmoles) and stirred at room temperature for 1 hr. Dilute hydrochloric acid (100 ml) was added and the product

extracted into diethyl ether. The organics were washed with dilute hydrochloric acid then brine and dried (Na_2SO_4). Evaporation of the solvent followed by flash chromatography on TLC silica gel eluting with dichloromethane gave the title compound (D3) (3.7g, 25%).

5

NMR (CDCl_3) δ : 1.25-1.45 (3H, m), 3.90 (3H, s), 4.25-4.40 (2H, m), 6.81-6.95 (2H, m), 7.41 (1H, d, $J=8\text{Hz}$)

Description 4

10 Ethyl 5-bromo-6-methoxybenzo[b]thiophene-3-carboxylate (D4)

Ethyl 3-(3-methoxy-4-bromophenylthio)-2-oxopropanoate (D3) (3.7g, 11 mmoles) in chlorobenzene (25 ml) was treated with phosphorus pentoxide (11.1g, 78 mmoles) and 85% phosphoric acid (5.5 ml). The mixture was heated under reflux for 6 hrs.

15 The mixture was allowed to cool and then partitioned between water (150 ml) and dichloromethane. The organics were washed several times with water then dried (Na_2SO_4). Evaporation to dryness followed by flash chromatography on TLC silica gel eluting with dichloromethane/60-80 petrol-ether 1:1 gave the title compound (D4) (0.94g, 27%).

20

NMR (CDCl_3) δ : 1.42 (3H, t, $J = 8\text{Hz}$), 3.95 (3H, s), 4.40 (2H, q, $J = 8\text{Hz}$), 7.30 (1H, s), 8.20 (1H, s), 8.78 (1H, s).

Description 5

25 5-Bromo-6-methoxybenzo[b]thiophene-3-carboxylic acid (D5)

Ethyl 5-bromo-6-methoxybenzo[b]thiophene-3-carboxylate (D4) (0.42g, 0.0013 mole) in ethanol (20 ml) and water (5 ml) was treated with sodium hydroxide powder (0.14g, 0.0035 mole). The reaction mixture was heated under reflux for 2 hours and stirred at ambient temperature for 16 hours. The solvent was removed *in vacuo* and the residue diluted with water (25 ml), acidified with 5N hydrochloric acid, extracted into ethyl acetate, dried (Na_2SO_4) and evaporated *in vacuo* to afford the title compound (0.36g, 93%) as a beige solid.

35 ^1H NMR (200 MHz; D^6DMSO)

δ : 3.08-3.60 (1H, br s), 3.93 (3H, s), 7.88 (1H, s), 8.52 (1H, s), 8.64 (1H, s).

Description 6**Ethyl 5-trifluoromethyl-6-methoxybenzo[b]thiophene-3-carboxylate (D6)**

5 Ethyl-5-bromo-6-methoxybenzo[b]thiophene-3-carboxylate (D4) (0.81g, 3 mmoles) in dry dimethylformamide (20 ml) and toluene (10 ml) was treated with potassium trifluoroacetate (0.78g, 6 mmoles) and copper (I) iodide (0.98g, 6 mmoles). The mixture was heated under reflux for 1 hr using a Dean-Stark trap to collect the toluene. The mixture was cooled and poured into water (150 ml) and extracted with diethyl ether. The resulting emulsion was filtered through kieselguhr. The combined
10 organic extracts were washed several times with water then dried (Na₂SO₄). Flash chromatography on TLC silica gel eluting with dichloromethane/60-80 petrol ether 1:1 gave the title compound (D6) (0.5g, 64%)

15 NMR (CDCl₃) δ: 1.45 (3H, t, J = 8Hz), 3.95 (3H, s), 4.40 (2H, q, J = 8Hz), 7.40 (1H, s), 8.25 (1H, s), 8.8 (1H, s)

Description 7**5-Trifluoromethyl-6-methoxybenzo[b]thiophene-3-carboxylic acid (D7)**

20 Ethyl 5-trifluoromethyl-6-methoxybenzo[b]thiophene-3-carboxylate (D6) (0.5g, 2 mmoles) was treated with sodium hydroxide as in the method of description 5 to give the title compound (D7) (0.42g, 92%)

25 NMR (DMSO) δ: 3.95 (3H, s), 8.0 (1H, s), 8.58 (1H, s), 8.21 (1H, s), 13.11-13.21 (1H, br s)

Description 8**3-Methoxy-4-bromophenol (D8)**

30 3-Methoxy-4-bromoaniline (D1) (10.0g, 49 mmoles) in water (60 ml) and concentrated sulphuric acid (30 ml) was treated with a solution of sodium nitrite (3.4g, 49 mmoles) in water (15 ml) dropwise keeping the temperature below 5° C. The resulting slurry was then added slowly to a mixture of water (60 ml) and concentrated sulphuric acid (30 ml) at 80° C and stirred at this temperature for 3 hrs.
35 The mixture was cooled and extracted with dichloromethane (2 x 200 ml). The organics were then extracted with 2N sodium hydroxide solutions (2 x 100 ml). The aqueous was washed with more dichloromethane (2 x 200 ml) then acidified to pH 1.

Extraction with dichloromethane, drying (Na_2SO_4) and evaporation to dryness gave the title compound (D8) (6.95g, 69%).

NMR (CDCl_3) δ : 3.85 (3H, s), 4.75-4.95 (1H, br s), 6.29-6.35 (1H, m), 6.45 (1H, s),
5 7.35 (1H, d, $J = 8\text{Hz}$).

Description 9

Ethyl 3-methoxy-4-bromophenoxyacetate (D9)

10 3-Methoxy-4-bromophenol D8 (6.95g, 34 mmoles) in dry dimethylformamide (100 ml) at 0°C was treated with sodium hydride (80% dispersion in oil) (1.13g, 37 mmoles). After 30 mins ethyl bromoacetate (3.8 ml, 34 mmoles) was added and the mixture allowed to warm to room temperature over 1 hr. The mixture was concentrated *in vacuo* and the residue partitioned between water and diethyl ether.
15 The organic layer was washed several times with water and then dried (Na_2SO_4) and evaporated to dryness. Flash chromatography on TLC silica gel eluting with dichloromethane gave the title compound (D9) (7.43g, 75%)

NMR (CDCl_3) δ : 1.30 (3H, t, $J = 8\text{Hz}$), 3.85 (3H, s), 4.28 (2H, q, $J = 8\text{Hz}$), 6.28-
20 6.32 (1H, m), 6.58 (1H, s), 7.40 (1H, d, $J = 10\text{Hz}$)

Description 10

Diethyl-3-methoxy-4-bromophenoxyoxalate (D10)

25 Diethyl oxalate (2.8 ml, 20 mmoles) was added to a suspension of sodium ethoxide (1.48g, 21 mmoles) in dry diethyl ether (30 ml) and stirred at room temperature for 15 mins. A solution of ethyl-3-methoxy-4-bromophenoxyacetate (D9) (6.0g, 20 mmoles) in diethyl ether (30 ml) was then added dropwise. The mixture was stirred at room temperature for 18 hrs then washed with 1N hydrochloric acid (2 x 100 ml),
30 water (100 ml), brine (100 ml) then dried (Na_2SO_4). Evaporation of solvent gave the title compound (D10) (7.84g, 97%).

NMR (CDCl_3) δ : 1.20-1.45 (6H, m), 3.80 (3H, s), 4.20-4.45 (4H, m), 6.31-6.42 (1H, m), 6.55-6.68 (1H, m), 7.37-7.45 (1H, m)

35

Description 11

Diethyl 5-bromo-6-methoxybenzo[b]furan-2,3-dicarboxylate (D11)

Diethyl 3-methoxy-4-bromophenoxyoxalacetate (D10) (7.8g, 20 mmoles) was stirred with concentrated sulphuric acid (50 ml) for 30 mins. The mixture was then poured into ice water (500 ml) and extracted with diethyl ether (250 ml). The organics were washed with saturated aqueous sodium bicarbonate, dried (Na_2SO_4) and evaporated to dryness. Flash chromatography on TLC silica gel eluting with dichloromethane gave the title compound (D11) (3.29g, 44%)

NMR (CDCl_3) δ : 1.37-1.50 (6H, m), 3.90 (3H, s), 4.39-4.53 (4H, m), 7.05 (1H, s), 8.07 (1H, s)

Description 12

5-Bromo-6-methoxybenzo[b]furan-2,3-dicarboxylic acid (D12)

Diethyl 5-bromo-6-methoxybenzo[b]furan-2,3-dicarboxylate (D11) (1.26g, 3.4 mmoles) in ethanol (20 ml) and water (5 ml) was treated with 20% sodium hydroxide solution (5 ml) and heated under reflux for 3 hrs. The mixture was cooled and the ethanol removed *in vacuo*. The mixture was acidified to pH1 with hydrochloric acid. Filtration of the solid and drying gave the title compound (D12) (0.91g, 85%)

NMR (DMSO-d_6) δ : 3.90 (3H, s), 7.50 (1H, s), 7.90-8.80 (3H including 2H, br s and 8.25 (1H, s))

Description 13

5-Bromo-6-methoxybenzo[b]furan-3-carboxylic acid (D13)

5-Bromo-6-methoxybenzo[b]furan-2,3-dicarboxylic acid (D12) (0.85g, 2.7 mmoles) was heated to its melting point ($\sim 270^\circ\text{C}$) for 15 mins (CO_2 evolution). The mixture was allowed to cool and the resulting black residue extracted with ethyl acetate. The organic solution was then filtered and the filtrate evaporated to dryness to give the title compound (D13) (0.65g, 89%)

NMR (DMSO-d_6) δ : 3.90 (3H, s), 7.51 (1H, s), 8.02 (1H, s), 8.60 (1H, s).

Description 14

Ethyl 5-bromo-6-methoxybenzo[b]furan-3-carboxylate (D14)

- 5-Bromo-6-methoxybenzo[b]furan-3-carboxylic acid (D13) (0.27g, 1 mmole) was heated under reflux for 1 hr in thionyl chloride. Cooling and evaporating to dryness gave the acid chloride which was treated with ethanol (10 ml) and triethylamine (1 ml). After 1 hr the mixture was evaporated to dryness and the residue partitioned between water and dichloromethane. The organic layer was dried (Na₂SO₄) and evaporated to dryness. Flash chromatography on TLC silica gel eluting with dichloromethane/60-80 petrol ether 50:50 gave the title compound (D14) (0.077g, 26%)
- 10 NMR (CDCl₃) δ: 1.40 (3H, t, J = 8Hz), 3.90 (3H, s), 4.39 (2H, q, J = 8Hz), 7.03 (1H, s), 8.13 (1H, s), 8.19 (1H, s)

Description 15

Ethyl 5-trifluoromethyl-6-methoxybenzo[b]furan-3-carboxylate (D15)

- 15 Ethyl-5-bromo-6-methoxybenzo[b]furan-3-carboxylate (D14) (0.077g, 0.3 mmoles) was converted to the title compound (D15) as in the method of description 6 (0.028g, 38%)
- 20 NMR (CDCl₃) δ: 1.40 (3H, t, J = 8Hz), 3.92 (3H, s), 4.40 (2H, q, J = 8Hz), 7.10 (1H, s), 8.20 (1H, s), 8.28 (1H, s).

Description 16

5-Trifluoromethyl-6-methoxybenzo[b]furan-3-carboxylic acid (D16)

- 25 Ethyl 5-trifluoromethyl-6-methoxybenzo[b]furan-3-carboxylate (D15) (0.028, 0.1 mmoles) was hydrolysed to the title compound (D16) as in the method of description 5 (0.022g, 90%)

30 Description 17

4-Bromo-3-methoxy-N-methylsulphonylanilide (D17)

- 35 Methanesulphonyl chloride (22.4 ml, 289 mmol) was added dropwise to a solution of aniline (D1, 56.1g, 277.7 mmol) and pyridine (23.1 ml, 277.7 mmol) in dry dichloromethane (600 ml) at 0° C. The mixture was stirred overnight, then washed with water three times, dried and concentrated to crystallise the product. A further crop was obtained by addition of petrol to the mother liquor and further

concentration. The two crops were combined to give the title compound (68.0g, 87%) mp 121-4° C.

5 NMR (CDCl₃) δ: 3.03 (3H, s), 3.91 (3H, s), 6.79 (1H, dd, J = 7,2), 6.89 (1H, d, J = 2), 7.49 (1H, d, J = 7)

Description 18

4-Bromo-N-(2,2-diethoxyethyl)-3-methoxy-N-methylsulphonyl anilide (D18)

10 A solution of sulphonylanilide (D17, 68.0g, 243 mmol) in dimethyl-formamide (350 ml) was added over 40 min to a suspension of sodium hydride (80% in oil, 8.1g, 269.5 mmol) in dimethylformamide (50 ml) at 0° C. After 30 min, when evolution of hydrogen had ceased, (2,2-diethoxyethyl)trifluoromethanesulphonate (77.8g, 292.5 mmol) was added as a steady stream. After 6h at room temperature further quantities
15 of sodium hydride (0.8g) and trifluoromethanesulphonate (8g) were added, and stirring was continued overnight. The mixture was then partially evaporated, diluted with water and extracted with toluene. The organic extract was washed well with water and brine, dried and evaporated. The residue was recrystallised twice from dichloromethane/petrol to give the title compound (39g, 40.5%), mp. 70-72° C.

20

NMR (CDCl₃) δ:

25 1.18 (3H, t, J = 7), 2.97 (3H, s), 3.51 (2H, m), 3.67 (2H, m), 3.75 (2H, d, J = 6), 3.90 (3H, s), 4.41 (1H, t, J = 6), 6.83 (1H, dd, J = 7, 2), 6.97 (1H, d, J = 2), 7.54 (1H, d, J = 7)

Description 19

5-Bromo-6-methoxy-1-methylsulphonylindole (D19)

30 A solution of titanium tetrachloride in toluene (138 ml of 1M solution diluted with 750 ml toluene) was added slowly to a solution of diethoxyethyl anilide (D18, 39g, 98.4 mmol) in toluene (2.0L) at 0° C. Internal temperature remained below 5° C during addition. The mixture was then heated until reflux began, maintained at reflux for 10 min, then cooled, washed with sat. sodium bicarbonate solution, dilute
35 hydrochloric acid and water, dried and evaporated. The residue was recrystallised from ether. The mother liquor was chromatographed on silica gel eluted with dichloromethane and eluted material was recrystallised from ether to give a second

crop. The two crops were combined to give the title compound (21.2g, 71%), mp. 126-129° C.

5 NMR (CDCl₃) δ: 3.09 (3H, s), 3.98 (3H, s), 6.61 (1H, d, J = 3), 7.34 (1H, d, J = 3), 7.48 (1H, s), 7.79 (1H, s)

Description 20

5-Bromo-6-methoxy indole (D20)

10 The 1-methylsulphonylindole (D19, 21.2g, 69.7 mmol) was heated under reflux in a mixture of 10% aqueous sodium hydroxide solution (170 ml) and ethanol (1.0 L) for 1.5 h. The mixture was evaporated almost to dryness, and the residue was dissolved in ethyl acetate and washed with water. The organic phase was dried and evaporated to give the title compound (15.65g, 99%), mp 110-111° C.

15

NMR (CDCl₃) δ: 3.90 (3H, s), 6.43 (1H, m), 6.91 (1H, s), 7.10 (1H, m), 7.80 (1H, s), 8.18 (1H, broad)

Description 21

5-Bromo-6-methoxy-3-trichloroacetyl indole (D21)

Trichloroacetyl chloride (8.5 ml, 76.1 mmol) was added to a solution of pyridine (6.1 ml, 76.1 mmol) in dry 1,4-dioxan (70 ml). After a few minutes of stirring, a solution of indole (D20, 15.65g, 69.2 mmol) in 1,4-dioxan (70 ml) was added slowly. The mixture was stirred for 24 h at room temperature, then poured into water. The precipitate was filtered off and washed with water, then recrystallised from ethanol/water to give the title compound (14.19g, 55%), mp. 185-190° C.

25 NMR (CDCl₃/CD₃OD) δ:
30 3.93 (3H, s), 6.97 (1H, s), 8.24 (1H, s), 8.58 (1H, s)

Description 22

5-Bromo-6-methoxyindole-3-carboxylic acid (D22)

35 The trichloroacetylindole (D21, 1.48g, 4 mmol) was heated in a mixture of 10% aqueous potassium hydroxide (3 ml) and tetrahydrofuran (15 ml) at 40-50° C over three nights. The mixture was poured into water and extracted with ether. The

ethereal phase was re-extracted with dil. potassium hydroxide solution, and the combined aqueous phases were acidified with 10% aq. hydrochloric acid and extracted with dichloromethane/methanol. This extract was dried and evaporated to give the title compound (0.74g, 68.5%)

5

NMR (CD₃OD) δ : 3.90 (3H, s), 7.07 (1H, s), 7.87 (1H, s), 8.19 (1H, s)

Description 23

5-Bromo-6-methoxy-1-methyl-3-trichloroacetylindole (D23)

10

The trichloroacetylindole (D21, 1.86g, 5 mmol) was added in small portions to a suspension of sodium hydride (80% in oil, 0.165g, 5.5 mmol) in dry dimethylformamide (20 ml). After stirring at room temperature for 20 min., methyl iodide (0.34 ml, 5.5 mmol) was added. After stirring for 1 h, the mixture was partially evaporated and the residue was poured into water. The precipitate was filtered off, washed with water and dried to give the title compound (1.75g, 91%)

15

NMR (CDCl₃) δ :

3.88 (3H, s), 3.98 (3H, s), 6.80 (1H, s), 8.09 (1H, s), 8.60 (1H, s).

20

Description 24

Methyl 5-bromo-6-methoxy-1-methylindole-3-carboxylate (D24)

The trichloroacetylindole (D23, 1.73g, 4.5 mmol) was heated under reflux in methanol (20 ml) containing 1 drop of 60% aqueous potassium hydroxide for 45 min. The mixture was then evaporated and the residue was slurried with water. The solid was filtered off and washed with water, then chromatographed on silica gel eluted with 0-2% methanol/dichloromethane to give the title compound (1.03g, 77%)

25

30 NMR (CDCl₃) δ : 3.79 (3H, s), 3.91 (3H, s), 3.96 (3H, s), 6.76 (1H, s), 7.67 (1H, s), 8.30 (1H, s)

Description 25

Methyl 6-methoxy-1-methyl-5-trifluoromethylindole-3-carboxylate (D25)

35

A mixture of methyl ester (D24, 1.01g, 3.4 mmol), potassium trifluoroacetate (1.04g, 6.8 mmol) and copper (I) iodide (1.27g, 6.8 mmol) in toluene (10 ml) and

dimethylformamide (20 ml) was heated to distil off toluene. The mixture was then heated at 148-150° C (internal) for 2 h. A further quantity of potassium trifluoroacetate (0.5g) was added and heating continued for 2 h. The mixture was then evaporated and the residue was extracted with dichloromethane/methanol. The
5 extract was filtered, washed with water, dried and evaporated. The residue was recrystallised from dichloromethane/petrol to give the title compound (0.67g, 69%), mp. 166-170° C.

10 NMR (CDCl₃) δ: 3.81 (3H, s), 3.92 (3H, s), 3.97 (3H, s), 6.81 (1H, s), 7.73 (1H, s), 8.37 (1H, s).

Description 26

6-Methoxy-1-methyl-5-trifluoromethylindole-3-carboxylic acid (D26)

15 The trifluoromethylindole ester (D25, 0.67g, 2.33 mmol) was heated under reflux in a mixture of 10% aqueous sodium hydroxide (5 ml) and methanol (10 ml) for 30 min. The mixture was then diluted with water to dissolve all solid and extracted with dichloromethane. The aqueous phase was acidified with 5M hydrochloric acid and the precipitate was filtered off and dried to give the title compound (0.56g, 88%), mp.
20 >247° C (decomp.)

NMR (d₆-DMSO) δ: 3.86 (3H, s), 3.94 (3H, s), 7.34 (1H, s), 8.03 (1H, s), 8.22 (1H, s)

25 Description 27

5-Chloro-6-methylbenzo [b] thiophene (D27)

The title compound was prepared by adding (3-methyl-4-chlorophenylthio)acetaldehyde diethyl acetal to polyphosphoric acid under reduced
30 pressure (1.5 mm Hg).^{*} This gave 1.8 g of a mixture of the title compound (D27) and 4-methyl-5-chlorobenzo[b]thiophene in a 60 : 40 ratio.

NMR (CDCl₃) δ : 2.40 (3H, s), 7.12 (1H, d, J = 6), 7.29 (1H, d, J = 6), 7.61 (1H, s),
35 7.70 (1H, s) + peaks for undesired isomer.

^{*} M.S. El Shanta and R.M. Scrawston, J. Chem. Soc. (C) 1967, 2084

Description 28**5-Chloro-6-methylbenzo [b] thiophene-3-carboxylic acid (D28)**

5 Friedel-Crafts acylation of the mixture containing 5-chloro-6-methylbenzo [b] thiophene (D27) and 4-methyl-5-chlorobenzo [b] thiophene with trichloroacetyl chloride/aluminium chloride followed by basic hydrolysis* gave the title compound (D28) (0.09g, 24%)

NMR (DMSO-d₆) δ : 2.40 (3H, s), 7.89 (1H, s), 8.00 (1H, s), 8.82 (1H, s).

10

Example 1**5-Bromo-6-methoxy-N-(3-pyridyl)benzo-[b]thiophene-3-carboxamide (E1)**

15 5-Bromo-6-methoxybenzo[b]thiophene-3-carboxylic acid (D5) (0.36g, 0.0013 mole) and thionyl chloride (20 ml) were heated under reflux for 1 hour, after which the reaction mixture was cooled to ambient temperature and evaporated *in vacuo*. The resulting acid chloride was dissolved in dry dichloromethane (30 ml) and acetonitrile (10 ml) under argon. 3-Aminopyridine (0.12g, 0.0013 mole) was added and the reaction mixture stirred at ambient temperature for 16 hours. The solvent was
20 removed *in vacuo* and the resulting solid basified with 10% sodium hydroxide solution, extracted into dichloromethane, dried (Na₂SO₄) and evaporated *in vacuo*. The resulting solid was recrystallised from ethyl acetate/methanol to afford the title compound (0.11g, 23%) as a beige solid.

25 ¹H NMR (270 MHz; D⁶DMSO) δ: 3.93 (3H, s), 7.42 (1H, q), 7.89 (1H, s), 8.20 (1H, dt), 8.34 (1H, d), 8.56 (1H, s), 8.64 (1H, s), 8.93 (1H, s), 10.55 (1H, s)

Example 2

30 **6-Methoxy-N-(3-pyridyl)-5-trifluoromethylbenzo[b]thiophene-3-carboxamide hydrochloride salt (E2)**

35 5-Trifluoromethyl-6-methoxybenzo[b]thiophene-3-carboxylic acid (D7) (0.39g, 1.4 mmoles) was converted to the title compound as in the method of example 1 isolating as the hydrochloride salt after recrystallising from methanol. (E2) (0.33g, 58%) m.p. >270° C.

* R. Bonjouklian, Syn. Comm., 1985, 15(8), 711-713

NMR (DMSO-d₆) δ: 3.97 (3H, s), 7.91-7.99 (1H, m), 8.03 (1H, s), 8.62 (1H, d, J = 6Hz), 8.72 (1H, s), 8.81 (1H, d, J = 6Hz), 9.01 (1H, s), 9.41 (1H, s), 11.51 (1H, s)

5 M⁺ = 352

C₁₆H₁₁N₂O₂SF₃ requires 352

Example 3

10 **5-Bromo-6-methoxy-N-(3-pyridyl)benzo[b]furan-3-carboxamide (E3)**

5-Bromo-6-methoxybenzo[b]furan-3-carboxylic acid (D13) (0.4g, 1.4 moles) was converted to the title compound (E3) as in the method of example 1 (0.29g, 58%) m.p. 210-212° C.

15

NMR (DMSO-d₆) δ: 3.91 (3H, s), 7.38-7.42 (1H, m), 7.52 (1H, s), 8.10-8.17 (1H, m), 8.20 (1H, s), 8.29-8.33 (1H, m), 8.70 (1H, s), 8.88 (1H, s).

M⁺ = 346 and 348

20 C₁₅H₁₁N₂O₃Br requires 346 and 348

Example 4

6-Methoxy-N-(3-pyridyl)-5-trifluoromethylbenzo[b]furan-3-carboxamide (E4)

25 5-Trifluoromethyl-6-methoxybenzo[b]furan-3-carboxylic acid (D16) (0.025g, 0.1 mmoles) was converted to the title compound as in the method of example 1 (0.025g, 83%) mp. 219-221° C.

30 NMR (DMSO-d₆) δ: 3.95 (3H, s), 7.35-7.42 (1H, m), 7.65 (1H, s), 8.12 (1H, d, J = 8Hz), 8.25-8.39 (2H, m), 8.80 (1H, s), 8.90 (1H, s)

Example 5

5-Bromo-6-methoxy-N-(3-pyridyl)indole-3-carboxamide (E5)

35 To a solution of acid (D22, 0.86g, 3.2 mmol) in dry tetrahydrofuran (30 ml) was added oxalyl chloride (0.27 ml, 3.2 mmol) and dimethylformamide (3 drops). After stirring for 1 h at room temperature the mixture was evaporated. Fresh

tetrahydrofuran (30 ml) was added, followed by a solution of 3-aminopyridine (0.30g, 3.2 mmol) and triethylamine (0.44 ml, 3.2 mmol) in tetrahydrofuran (10 ml). The mixture was stirred at room temperature overnight, then evaporated. The residue was dissolved in dichloromethane/methanol and this solution was washed with water,
5 saturated aqueous potassium carbonate and brine, dried and evaporated. The crude product was chromatographed on silica gel eluted with 10% methanol/dichloromethane to give the title compound (0.29g, 26%), mp. >250° C.

NMR (d_6 -DMSO) δ : 3.88 (3H, s), 7.15 (1H, s), 7.38 (1H, dd, J = 7, 5), 8.19 (1H, dm, J = 7), 8.27 (2H, m), 8.33 (1H, s), 8.90 (1H, d, J = 2), 9.96 (1H, s), 11.77 (1H, s).
10

MS (EI) m/e = 347 (M^+)

Example 6

15 **6-Methoxy-1-methyl-N-(3-pyridyl)-5-trifluoromethylindole-3-carboxamide (E6)**

This compound was prepared by the method of Example 5, from acid (D26, 0.55g, 2.0 mmol) and 3-aminopyridine (0.19g, 2.0 mmol), with other reagents and solvents in proportionate quantities. After addition of the aminopyridine, the mixture was
20 stirred for 4 h at room temperature, then poured into water. The precipitate was filtered off, washed with water and dried. The crude product was recrystallised from dichloromethane/methanol to give the title compound (0.55g, 79%), mp. >250° C.

NMR (d_6 -DMSO) δ : 3.92 (3H, s), 3.97 (3H, s), 7.39 (2H, m), 8.20 (1H, d, J = 8),
25 8.28 (1H, d, J = 5), 8.31 (1H, s), 8.45 (1H, s), 8.90 (1H, d, J = 2), 10.07 (1H, s)

MS (EI) m/e = 349 (M^+)

Example 7

30 **5-Chloro-6-methyl-N-(3-pyridyl)benzo [b] thiophene-3-carboxamide hydrochloride (E7)**

5-Chloro-6-methylbenzo [b] thiophene-3-carboxylic acid (D2) (0.09g, 0.4 mmoles) was treated with thionyl chloride (10 ml) and heated under reflux for 2 hrs. The
35 mixture was evaporated to dryness and the resulting acid chloride was re-dissolved in dichloromethane (10 ml) and treated with 3-aminopyridine (0.038 g, 0.4 mmoles). After 4hrs the precipitate was filtered off. Recrystallisation from methanol gave the

title compound (E1) (0.04g, 30%) m.p. 160-1° C

NMR (DMSO-d₆) δ : 2.45 (3H, s), 7.73-7.81 (1H, m), 8.11 (1H, s), 8.47-8.53 (3H, m), 8.80 (1H, s), 9.20 (1H, s), 11.01 (1H, s).

5

Found M⁺ 302, 304

C₁₅H₁₁N₂O₅Cl requires 302, 304

Example 8

10

5-Thiomethyl-6-trifluoromethyl-1-(3-pyridylcarbamoyl)-indole (E8)

A solution of 5-methylthio-1-(3-pyridylcarbamoyl)-6-trifluoromethyl indoline (WO 95/01976) (500 mg, 1.4 mmol) in acetic acid (10 ml) under argon atmosphere was treated with manganese triacetate (415 mg, 1.53 mmol) and heated under reflux for 4 days. Work-up of the solution (neutralisation of the solution with sodium bicarbonate solution, filtration and extraction of the aqueous into dichloromethane) afforded a mixture which was separated by HPLC to yield a green powder (20 mg).

¹H NMR 250 MHz d⁶-DMSO δ: 2.51 (s, 3H), 6.88 (d, 2H), 7.45 (m, 1H), 7.84 (s, 1H), 8.09 (m, 1H), 8.26 (d, 1H), 8.38 (d, 1H), 8.60 (s, 1H), 8.80 (m, 1H).

20

Mass. spec. M⁺ m/z = 351 (10%)

Pharmacological data

**[³H]-mesulergine binding to rat or human 5-HT_{2C} clones expressed in 293 cells
in vitro**


5

Compounds were tested following the procedure outlined in WO 94/04533.

The compounds of examples 3 to 8 have pK_i values of at least 7.2

Claims:

1. A compound of formula (I) or a salt thereof:



5

wherein:

P represents phenyl, a quinoline or isoquinoline residue, or a 5-membered or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;

- 10 X and Y are independently selected from oxygen, sulphur, carbon, nitrogen, C=O, CH, CH₂ or NR⁴ where R⁴ is hydrogen or C₁₋₆ alkyl;

Z is carbon, nitrogen or CH and the dotted lines represent optional double bonds;

R¹ is hydrogen, C₁₋₆ alkyl, halogen, CF₃, NR⁷R⁸ or OR⁹ where R⁷, R⁸ and R⁹ are independently hydrogen, C₁₋₆ alkyl or arylC₁₋₆alkyl;

- 15 R² is hydrogen or C₁₋₆ alkyl;

n is 0 to 3; and

R³ groups are independently C₁₋₆ alkyl optionally substituted by one or more halogen atoms, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₆ alkyl, C₁₋₆ alkylthio, C₃₋₆cycloalkylthio, C₃₋₆ cycloalkylC₁₋₆ alkylthio,

- 20 halogen, nitro, CF₃, OCF₃, SCF₃, SO₂CF₃, SO₂F, formyl, C₂₋₆ alkanoyl, cyano, optionally substituted phenyl or thienyl, NR⁷R⁸, CONR⁷R⁸, or OR⁹ where R⁷, R⁸ and R⁹ are as defined for R¹, CO₂R¹⁰ where R¹⁰ is hydrogen or C₁₋₆ alkyl; or two adjacent R³ groups together form an optionally substituted 5-membered heterocyclic ring;

- 25 provided that when X and Y are both CH₂, Z is other than nitrogen.

2. A compound according to claim 1 in which R¹ is hydrogen.

3. A compound according to claim 1 or 2 in which R² is hydrogen.

4. A compound according to any one of claims 1 to 3 in which n is 2.

5. A compound according to any one of claims 1 to 4 in which P is pyridine.

- 30 6. A compound according to claim 1 which is:

5-Bromo-6-methoxy-N-(3-pyridyl)benzo-[b]thiophene-3-carboxamide,

6-Methoxy-N-(3-pyridyl)-5-trifluoromethylbenzo[b]thiophene-3-carboxamide,

5-Bromo-6-methoxy-N-(3-pyridyl)benzo[b]furan-3-carboxamide,

6-Methoxy-N-(3-pyridyl)-5-trifluoromethylbenzo[b]furan-3-carboxamide,

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/02637

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D409/12 A61K31/33 C07D405/12 C07D401/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 9134 Derwent Publications Ltd., London, GB; AN 91-248708 & JP,A,03 161 470 (NISSHIN FLOUR MILL KK) , 11 July 1991 see abstract ---	1-10
A	WO,A,92 05170 (BEECHAM GROUP PLC) 2 April 1992 see abstract; claim 1 ---	1-10
A	WO,A,94 14801 (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); MARTIN ROGER THOM) 7 July 1994 see the whole document --- -/--	1-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

26 October 1995

Date of mailing of the international search report

- 7. 11. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/02637

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP,A,0 610 553 (SQUIBB & SONS INC) 17 August 1994 see abstract; claims; example 8 ---	1-8
P,X	WO,A,95 01976 (SMITHKLINE BEECHAM PLC ;HAM PETER (GB); JONES GRAHAM ELGIN (GB); F) 19 January 1995 see the whole document ---	1-10
P,X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 14, 1995 WASHINGTON US, pages 2524-2530, I.T. FORBES ET AL. '5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-t etrahydropyrrolo[2,3-f]indole: ...' see page 2525, column 2, scheme 2; abstract ---	1-10
P,X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 1, 1995 WASHINGTON US, pages 58-67, B. D. PALMER 'Tyrosine Kinase Inhibitors. 4. ...' see page 62, column 1; table 2 -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/02637

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9205170	02-04-92	AU-B- 642041	07-10-93
		AU-B- 8503891	15-04-92
		CA-A- 2091246	14-03-92
		EP-A- 0550507	14-07-93
		JP-T- 6500551	20-01-94
		US-A- 5328922	12-07-94
WO-A-9414801	07-07-94	NONE	
EP-A-0610553	17-08-94	AU-B- 5065393	02-06-94
		CA-A- 2109186	18-05-94
		JP-A- 6228092	16-08-94
WO-A-9501976	19-01-95	AU-B- 7228394	06-02-95

INTERNATIONAL SEARCH REPORT

national application No.

PCT/EP 95/02637

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Reason:
→ The claims 1 - 5 encompass such an enormous amount of compounds that carrying out a complete search is impossible on economic grounds, because the broadness of the claims is such that even by means of on-line searching techniques a complete search appears not to be possible. For this reason the search has been restricted to the embodiments of the claims sufficiently supported by the description, i.e. the examples and claim 6.

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.